08.16.12
Broomfield, Colo.-based Lanx Inc. has been granted a patent for is Aspen MIS (minimally invasive spine) Fusion System technology, designed to support spinal fusion.
“This new patent validates unique features of the Aspen system and reinforces the value that the Lanx research and development team has brought to the field of spine care,” said Dan Gladney, CEO of Lanx. “The Aspen system has been shown to be ideal to support fusion through a tissue-sparing technique, with over 25,000 implantations to date. We are pleased that the advanced engineering and design of the technology has been formally recognized. This is an important addition to our current patent portfolio and we expect additional patents to be granted in the future. We believe the patent granted today will support our competitive advantage as we introduce new innovations for spinal fixation and fusion, with a particular focus on less invasive treatment options like the Aspen system.”
According to Lanx, more than 1,000 surgeons worldwide have used the Aspen system for the treatment of degenerative disc disease, spondylolisthesis, spinal trauma or spinal tumor since 2007. Spondylolisthesis is a condition in which a vertebra in the lower part of the spine slips out of the proper position onto the bone below it. The patented device features proprietary spiked fixation plates designed to be rigidly affixed to the spinous process with the use of streamlined surgical instrumentation. The central barrel allows the implant to share weight with the fixation plates while restoring foraminal height, and also serves as a bone graft containment chamber to promote fusion. In addition, the device has an offset shape for optimized anatomical fit.
Currently, the Aspen system is being used to support posterolateral fusions and interbody fusions with data demonstrating fixation strength and stability comparable to pedicle screw constructs. Posterolateral fusion places a bone graft in the region outside the spine known as the posterolateral region. Interbody fusions add bone graft within the spine itself.
“Clinical data continues to substantiate the versatility and minimally invasive nature of the Aspen device, which I have seen firsthand in my practice,” said Robert Tatsumi, M.D., of Pacific Spine Specialists in Tualatin, Ore. “For many patients who require spinal fusion, the Aspen device provides robust stabilization and promotes fusion while requiring a smaller incision, less muscle trauma, less blood loss, a shorter surgery time and shorter recovery time than standard pedicle screw instrumentation.”
Founded in 2003, Lanx develops and markets spine fusion technologies with a focus on minimally invasive and biologics products.
“This new patent validates unique features of the Aspen system and reinforces the value that the Lanx research and development team has brought to the field of spine care,” said Dan Gladney, CEO of Lanx. “The Aspen system has been shown to be ideal to support fusion through a tissue-sparing technique, with over 25,000 implantations to date. We are pleased that the advanced engineering and design of the technology has been formally recognized. This is an important addition to our current patent portfolio and we expect additional patents to be granted in the future. We believe the patent granted today will support our competitive advantage as we introduce new innovations for spinal fixation and fusion, with a particular focus on less invasive treatment options like the Aspen system.”
According to Lanx, more than 1,000 surgeons worldwide have used the Aspen system for the treatment of degenerative disc disease, spondylolisthesis, spinal trauma or spinal tumor since 2007. Spondylolisthesis is a condition in which a vertebra in the lower part of the spine slips out of the proper position onto the bone below it. The patented device features proprietary spiked fixation plates designed to be rigidly affixed to the spinous process with the use of streamlined surgical instrumentation. The central barrel allows the implant to share weight with the fixation plates while restoring foraminal height, and also serves as a bone graft containment chamber to promote fusion. In addition, the device has an offset shape for optimized anatomical fit.
Currently, the Aspen system is being used to support posterolateral fusions and interbody fusions with data demonstrating fixation strength and stability comparable to pedicle screw constructs. Posterolateral fusion places a bone graft in the region outside the spine known as the posterolateral region. Interbody fusions add bone graft within the spine itself.
“Clinical data continues to substantiate the versatility and minimally invasive nature of the Aspen device, which I have seen firsthand in my practice,” said Robert Tatsumi, M.D., of Pacific Spine Specialists in Tualatin, Ore. “For many patients who require spinal fusion, the Aspen device provides robust stabilization and promotes fusion while requiring a smaller incision, less muscle trauma, less blood loss, a shorter surgery time and shorter recovery time than standard pedicle screw instrumentation.”
Founded in 2003, Lanx develops and markets spine fusion technologies with a focus on minimally invasive and biologics products.